Monday, January 2, 2012
In the Zone
$INHX - Inhibitex, Inc.
Inhibitex, Inc., a biopharmaceutical company, focuses on the development of differentiated anti-infective products to prevent or treat serious infections. It primarily focuses to treat shingles caused by the varicella zoster virus and chronic infections caused by hepatitis C virus (HCV).
Its antiviral product candidates include INX-189, a HCV nucleoside polymerase inhibitor that has completed Phase Ib clinical trials for the treatment of chronic hepatitis C infection; FV-100, an orally available nucleoside analogue prodrug, which is in Phase II clinical trials for the treatment of herpes zoster or shingles.
The company is also developing anti-bacterials comprising Staphylococcal Vaccines, which is under Phase I clinical trials to prevent Staphylococcus aureus infections; and Aurexis, a humanized monoclonal antibody that has completed Phase II trials for the treatment of Staphylococcus aureus bloodstream infections in hospitalized patients.
It has a license and development collaboration agreement with Pfizer, Inc. for the development of Staphylococcus aureus vaccine for humans. Inhibitex, Inc. was founded in 1994 and is based in Alpharetta, Georgia.
Please keep $INHX - Inhibitex, Inc. on your watch list for a breakout above the $11.20 to $11.25 on heavier than average daily trading volume of 2.91 million.
As the last week of 2011 came to a close Inhibitex, Inc. ended the week trading at $10.94 up $0.32 or +3.01% on lighter than average weekly trading volume of 3.22 million. The average weekly trading volume for Inhibitex, Inc. is 11.20 million.
This is not a buy recommendation please do your own due diligence or get help from a professional before trading.
By: Marlin Rolle
*** Please have a close look at the charts listed below ****